-
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks.
Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;35:662-70. -
Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.
Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;35:680-7. -
Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia.
Akolekar R, Cruz JJ, Foidart JM, Munaut C, Nicolaides KH.
Prenat Diagn 2010;30:191-7. -
Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation.
Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:871-6. -
Physiological distribution of placental growth factor and soluble Flt-1 in early pregnancy.
Makrydimas G, Sotiriadis A, Savvidou MD, Spencer K, Nicolaides KH.
Prenat Diagn 2008;28:175-9.